Evidence map›Paper›PMID 39653501›Full record

ArticleJournal of clinical pathology2025

Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (

Ekkehard Hewer, Pascal David Fischer, Erik Vassella, Laura Knabben, Sara Imboden, Michael D Mueller, Tilman T Rau, Matthias S Dettmer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ekkehard HewerInstitute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ekkehard.hewer@unil.ch m.dettmer@klinikum-stuttgart.de.ORCID http://orcid.org/0000-0002-9128-0364
Pascal David FischerInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Erik VassellaInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0001-7982-8713
Laura KnabbenDepartment of Gynaecology and Obstetrics, Bern University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland.
Sara ImbodenDepartment of Gynaecology and Obstetrics, Bern University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland.
Michael D MuellerDepartment of Gynaecology and Obstetrics, Bern University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland.
Tilman T RauInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-1251-950X
Matthias S DettmerInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland ekkehard.hewer@unil.ch m.dettmer@klinikum-stuttgart.de.ORCID http://orcid.org/0000-0003-0948-1392

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsMutations affecting exon 3 of the β-catenin (

methodsWe therefore examined lymphoid enhancer-binding factor 1 (LEF1) immunostaining, a nuclear marker of WNT activation that serves as a potential surrogate for

resultsIn a cohort of endometrial carcinomas with known mutation status (n=130) LEF1 was 85% accurate in predicting

conclusionWe conclude that LEF1 immunostaining is a useful surrogate marker for

Indexed as

beta CateninBiomarkers, TumorEndometrial NeoplasmsImmunohistochemistryLymphoid Enhancer-Binding Factor 1MutationDNA Mutational AnalysisFemaleHumansPredictive Value of Testsbeta CateninBiomarkers, TumorCTNNB1 protein, humanLEF1 protein, humanLymphoid Enhancer-Binding Factor 1CARCINOMAENDOMETRIUMGenes, NeoplasmIMMUNOHISTOCHEMISTRY

Identifiers

PMID39653501
PMCPMC12772540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.